No Data
No Data
Be Wary Of Double Medical Technology (SZSE:002901) And Its Returns On Capital
Double Medical Technology Inc. (002901.SZ) distributes profits in 2023: 2.50 yuan per 10 shares.
Double Medical Technology Inc. (002901.SZ) released an announcement on the profit distribution plan for the year 2023, which is based on the current situation of the company...
Double Medical Technology Inc. (002901.SZ): The first largest shareholder and the actual controller plan to transfer shares through an internal agreement.
On June 4th, Gelonhui announced that the first largest shareholder Guangxi Dabo Shangtong Venture Investment Co., Ltd. of Double Medical Technology Inc. (002901.SZ) had signed an equity transfer agreement with the company's actual controller Mr. Lin Zhixiong on June 4th, 2024. They intend to transfer their holdings of 179,928,000 shares of unrestricted tradable shares of the company (43.46% of the total share capital of the company) at a price of 25.52 yuan/share through the agreement. The first largest shareholder of the company, Dabo Shangtong, is the consistent acting person of the actual controller of the company, Mr. Lin Zhixiong. This share transfer agreement between the first largest shareholder and him.
Is The Market Rewarding Double Medical Technology Inc. (SZSE:002901) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Cathay Pacific Junan: The valuation level of the normalized mining industry is expected to rise
The Zhitong Finance App learned that Guotai Junan released a research report saying that in recent years, the quality of collection has been improved and expanded. Along with this, the design of collection rules has been continuously improved, and the results are more moderate and predictable. The results of this joint China Mining contract renewal have provided further verification. As the negative effects of traditional product collection are gradually clarified, emerging varieties are rapidly being admitted to hospital through collection. The number of surgeries is expected to continue to grow under the combined impetus of factors such as an aging population, increased public health awareness, and more mature procedures. The high-value consumables industry is also expected to continue to flourish on a new base, and the industry's valuation level is expected to rise. Maintain Elken Healthcare (0178
Dabo Healthcare (002901.SZ): Net profit of 61,728,900 yuan in the first quarter increased 6.05% year-on-year
On April 29, Ge Longhui (002901.SZ) released its report for the first quarter of 2024, with operating income of 427 million yuan, up 9.17% year on year; net profit attributable to shareholders of listed companies was 61.7289 million yuan, up 6.05% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 49.363 million yuan, up 4.48% year on year; basic earnings per share were 0.15 yuan.
No Data